Annals of Clinical and Translational Neurology (May 2021)

Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment

  • Maren Freigang,
  • Claudia D. Wurster,
  • Tim Hagenacker,
  • Benjamin Stolte,
  • Markus Weiler,
  • Christoph Kamm,
  • Olivia Schreiber‐Katz,
  • Alma Osmanovic,
  • Susanne Petri,
  • Alexander Kowski,
  • Thomas Meyer,
  • Jan C. Koch,
  • Isabell Cordts,
  • Marcus Deschauer,
  • Paul Lingor,
  • Elisa Aust,
  • Daniel Petzold,
  • Albert C. Ludolph,
  • Björn Falkenburger,
  • Andreas Hermann,
  • René Günther

DOI
https://doi.org/10.1002/acn3.51340
Journal volume & issue
Vol. 8, no. 5
pp. 1049 – 1063

Abstract

Read online

Abstract Objective To determine whether serum creatine kinase activity (CK) and serum creatinine concentration (Crn) are prognostic and predictive biomarkers for disease severity, disease progression, and nusinersen treatment effects in adult patients with 5q‐associated spinal muscular atrophy (SMA). Methods Within this retrospective, multicenter observational study in 206 adult patients with SMA, we determined clinical subtypes (SMA types, ambulatory ability) and repeatedly measured CK and Crn and examined disease severity scores (Hammersmith Functional Motor Scale Expanded, Revised Upper Limb Module, and revised Amyotrophic Lateral Sclerosis Functional Rating Scale). Patients were followed under nusinersen treatment for 18 months. Results CK and Crn differed between clinical subtypes and correlated strongly with disease severity scores (e.g., for Hammersmith Functional Motor Scale Expanded: (CK) ρ = 0.786/ (Crn) ρ = 0.558). During the 18 months of nusinersen treatment, CK decreased (∆CK = −17.56%, p < 0.0001), whereas Crn slightly increased (∆Crn = +4.75%, p < 0.05). Interpretation Serum creatine kinase activity and serum creatinine concentration reflect disease severity of spinal muscular atrophy and are promising biomarkers to assess patients with spinal muscular atrophy during disease course and to predict treatment response. The decrease of creatine kinase activity, combined with the tendency of creatinine concentration to increase during nusinersen treatment, suggests reduced muscle mass wasting with improved muscle energy metabolism.